New publication: Validating a bespoke 96-well plate for high-throughput drug susceptibility testing of M. tuberculosis Philip Fowler, 28th August 201829th September 2018 0 shares This paper, published in Antimicrobial Agents and Chemotherapy, determines the reproducibility and accuracy of minimum inhibitory concentrations for a panel of 14 different anti-TB compounds using a specifically designed 96-well plate (called UKMYC5) manufactured by Thermo Fisher. Since the UKMYC5 plate is being used by the CRyPTIC consortium to measure the drug susceptibility profiles of >30,000 clinical TB samples collected worldwide between now and 2020, this manuscript lays the foundations for this large and ambitious tuberculosis research project. It is free to read and download, and the paper briefly mentions my AMyGDA software which we will be using as an independent measuring technique to quality control the measurements made by the laboratory scientists. You can download and AMyGDA software from here. A manuscript is currently under review – you can read a preprint here. The bacterial growth on the UKMYC5 plates are also being classified by a Citizen Science project I have setup, BashTheBug. Share this:Twitter Related antimicrobial resistance clinical microbiology publication tuberculosis
antimicrobial resistance FowlerLab at ESM 2024 1st July 20241st July 2024 Three of us (Dylan Adlard, Dylan Dissanayake and Philip Fowler) attended the 44th Congress of… Share this:Twitter Read More
antimicrobial resistance New Publication: Predicting whether mutations confer resistance to an antibiotic 5th January 201829th September 2018 Due to the rise of antibiotic resistance, it is increasingly important that your clinician knows… Share this:Twitter Read More
tuberculosis Kafka and tuberculosis 21st June 20241st July 2024 To mark the centenary of Franz Kafka’s death from laryngeal tuberculosis at the age of… Share this:Twitter Read More